2021 / 05

Next Paper
DOI: 10.24075/brsmu.2021.046

ORIGINAL RESEARCH

Assessment of COVID-19 clinical course in patients vaccinated with Spitnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity

Kolobukhina LV1,3, Burgasova OA1,2,3, Kruzhkova IS1,3, Bakalin VV2, Generalova LV2, Shagaev AV3, Ogarkova DA1, Nikiforova MA1, Vasina DV1, Gushchin VA1,4, Smetanina SV3
About authors

1 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

2 Peoples’ Friendship University of Russia, Moscow, Russia

3 Infectious Clinical Hospital № 1, Moscow, Russia

4 Lomonosov Moscow State University, Moscow, Russia

Correspondence should be addressed: Ludmila V. Kolobukhina
Gamaleya St. 18, Moscow, 123098; ur.xednay@anihcubolokl

About paper

Acknowledgements: we would like to thank Antipyat NA, Deputy Chief Physician for Medical Affairs, and Bazarova MV, PhD, Deputy Chief Physician for Sanitary and Epidemiological Issues, Infectious Clinical Hospital № 1, for the study management and support.

Author contributions: Kolobukhina LV — study proponent, design, manuscript writing, clinical research management; Burgasova OA — literature analysis, manuscript writing and editing, clinical research data processing; Kruzhkova IS — clinical observation, literature analysis, processing of the results; Bakalin VV — clinical observation, clinical and laboratory data processing; Generalova LV — clinical data processing; Shagaev AV — monitoring of infected individuals after vaccination; Ogarkova DA — statistical analysis; Nikiforova MA — coordination of virological studies, virus isolation and VNA; Vasina DV — ELISA data processing, coordination of immunological studies; Gushchin VA — study concept, molecular biological and virological research management; Smetanina SV — clinical research general management.

Compliance with ethical standards: the study was approved by the Ethics Committee of Moscow Infectious Clinical Hospital (protocol № 11/А dated November 16, 2020). The informed consent was submitted by all patients.

Received: 2021-09-29 Accepted: 2021-10-13 Published online: 2021-10-17
|
  1. Kolobukhina LV, Burgasova OA, Kraeva LA, Gushchin VA, Burtseva EI, Kruzhkova IS, et al. Clinical and laboratory profile of patients with COVID-19 hospitalized in an infectious hospital in Moscow in the period from May to July 2020. Infectious diseases. 2021; 19 (2): 5–15. Russian.
  2. Rzymski P, Pazgan-Simon M, Krzysztof Simon T, ZarębskaMichaluk D, Szczepańska B, et al. Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. 2021; 9 (7): 78. Available from: https://www.mdpi.com/2076-393X/9/7/781.
  3. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an RAD26 and RAD5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021; 397 (10275): 671.
  4. Statistics and Research Coronavirus (COVID-19) Vaccinations. Available from: https://ourworldindata.org/covid-vaccinations.
  5. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20 (5): 533– 4. DOI: 10.1016/S1473-3099(20)30120-1. Erratum in: Lancet Infect Dis. 2020 Sep; 20 (9): e215.
  6. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397 (10287): 1819–829. DOI: 10.1016/S01406736(21)00947-8.
  7. Hodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021; ciab438. DOI: 10.1093/ cid/ciab438. Epub ahead of print. PMID: 33999127.
  8. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020; 396 (10255): 887–97.
  9. Keehner J, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021; 384: 1774–5. DOI: 10.1056/NEJMc2101927.
  10. NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care. Available from: https://www.cebm. net/covid-19/should-we-use-the-news-or-news2-score-whenassessing-patients-with-possible-covid-19-in-primary-care/.
  11. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020; 58 (1): e108. DOI: 10.1002/cpmc.108.
  12. V kakih stranah vakcina "Sputnik V" odobrena k primeneniju. Dostupno po ssylke: https://sputnik-meedia.ee/ infographics/20210607/573214/V-kakikh-stranakh-vaktsinaSputnik-V-odobrena-k-primeneniyu.html. Russian.
  13. Statistika vakcinacii ot koronavirusa (COVID-19) v Rossii. Dostupno po ssylke: https://index.minfin.com.ua/reference/ coronavirus/vaccination/russia/. Russian.
  14. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020; 217 (11): e20201181–e20201181.
  15. Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq. 2021; 3: 228079. DOI: 10.21203/rs.3.rs-228079/v1. Preprint.